DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of Long-acting Growth Hormone VRS-317 to Daily Growth Hormone in Pediatric GHD Patients

Information source: Versartis Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Growth Disorders

Intervention: VRS-317 (Drug); Daily rhGH (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Versartis Inc.

Official(s) and/or principal investigator(s):
George M Bright, MD, Study Director, Affiliation: Sponsor GmbH

Overall contact:
Eric Humphriss, MBA, Phone: 650-963-8587, Email: ehumphriss@versartis.com


The trial will compare a semi-monthly VRS-317 dosing regimen for non-inferiority of treatment effect against daily injections of rhGH.

Clinical Details

Official title: Comparison of VRS-317, a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy (Annual height velocity)

Secondary outcome:

Pharmacodynamics (IGF-I and IGFBP-3 responses to study drug administration)

Safety as measured by he number of patients with adverse events, concomitant medications, safety labs, vital signs, physical exams, and repeat dose immunogenicity.

Detailed description: This study is designed as a pivotal study to compare the safety and efficacy of a selected dose regimen of VRS-317 to daily rhGH. The study is a randomized, multi-center, open label study of 12 months duration. The primary endpoint is height velocity at 12 months.


Minimum age: 3 Years. Maximum age: 11 Years. Gender(s): Both.


Inclusion Criteria:

- Chronological Age ≥ 3. 0 years and ≤ 10. 0 (girls) and ≤ 11. 0 (boys).

- Pre-pubertal status: Absent breast development in girls, testicular volume < 4. 0 mL

in boys.

- Diagnosis of GHD as documented by two or more GH stimulation test results ≤ 10. 0


- Height SD score ≤ -2. 0 at screening.

- Weight for Stature ≥ 10th percentile.

- IGF-I SD score ≤ -1. 0 at screening.

- Delayed bone age (≥ 6 months).

Exclusion Criteria:

- Prior treatment with any growth promoting agent

- History of or concurrent significant disease (e. g. diabetes, cystic fibrosis, renal


- Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD)

or confirmed diagnosis of a named syndrome.

- A diagnosis of Attention Deficit Hyperactivity Disorder.

- Daily use of anti-inflammatory doses of glucocorticoid.

- Prior history of leukemia, lymphoma, sarcoma or cancer.

- Treatment with an investigational drug in the 30 days prior to screening.

- Known allergy to constituents of the study drug formulation.

- Ocular findings suggestive of increased intracranial pressure and/or retinopathy at


- Significant spinal abnormalities including scoliosis, kyphosis and spina bifida


- Significant abnormality in screening laboratory studies

Locations and Contacts

Eric Humphriss, MBA, Phone: 650-963-8587, Email: ehumphriss@versartis.com

Tallahassee, Florida, United States; Recruiting
Eric Humphriss, MBA, Phone: 650-963-8587, Email: ehumphriss@versartis.com
Naureen Sheikh, PhD, Phone: 650-433-2613, Email: nsheikh@versartis.com
Additional Information

Starting date: January 2015
Last updated: August 12, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017